Assembly Biosciences, Inc.
NASDAQ:ASMBBiotechnology
+$0.16 today
- Market cap
- $458.48M
- Beta
- 1.08
- P/E (TTM)
- -64.4
- EPS (TTM)
- -$0.38
Volume 0.49M
Average 0.17M
ASMB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Assembly Biosciences, Inc.NASDAQ: ASMB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $14.9M rose 0.3% year over year, behind the +10.1% change in trailing-twelve-month research & development. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at -2.5% a year.
Context
- Research & development amounted to 89.6% of revenue in FY2025, down 106.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +0.3% toward the trailing-twelve-month pace of +10.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 64.81M USD
- Year-over-year change
- +15.9%
- 4-year CAGR
- -1.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.81M | +15.9% |
| FY2024 | 2024-12-31 | 55.93M | +14.4% |
| FY2023 | 2023-12-31 | 48.9M | -30.1% |
| FY2022 | 2022-12-31 | 69.98M | +2.1% |
| FY2021 | 2021-12-31 | 68.52M | — |
Research & Development vs competitors
How ASMB compares with its peers on the latest reported figures
- ASMB's LTM Mar 2026 research & development of $64.86M is the 4th highest of the 6 companies compared; the peer median is $91.32M.
- Its year-over-year change of +10.1% is the 2nd highest of 6, against a peer median of -17.1%.
- Research & development amounts to 91.2% of revenue for ASMB, versus a peer median of 131.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $446.24M | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $20.4M | -57.1% | -33.1% | 10.7% | |
| LTM Mar 2026 | $7.02M | -17.1% | +13.9% | — | |
| Peer median (excluding ASMB) | $91.32M | -17.1% | -3.0% | 131.9% | |
Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.25M | 0 | 7.16M | 28.52M | 72.3M |
| Cost of Revenue | 0 | 69.08M | 48.9M | 55.93M | 129K |
| Gross Profit | 6.25M | (69.08M) | (41.74M) | (27.41M) | 72.17M |
| Gross Margin | 100.0% | — | -582.7% | -96.1% | 99.8% |
| Research & Development | 68.52M | 69.98M | 48.9M | 55.93M | 64.81M |
| Selling, General & Admin | 28.78M | 23.93M | 22.91M | 18.01M | 19.61M |
| Operating Expenses | 138.94M | 25.03M | 22.91M | 18.01M | 84.42M |
| Depreciation & Amortization | 466K | 498K | 450K | 129K | 129K |
| EBITDA | (90.58M) | (92.52M) | (60.75M) | (39.72M) | (5.99M) |
| EBITDA Margin | -1448.4% | — | -848.0% | -139.3% | -8.3% |
| Operating Income | (132.69M) | (94.11M) | (64.65M) | (45.42M) | (12.12M) |
| Operating Margin | -2121.7% | — | -902.5% | -159.3% | -16.8% |
| Interest Income | 302K | 1.02M | 3.45M | 5.57M | 6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 302K | 1.02M | 3.45M | 5.57M | 6M |
| Income Before Tax | (132.39M) | (93.09M) | (61.2M) | (39.85M) | (6.12M) |
| Pre-Tax Margin | -2116.8% | — | -854.3% | -139.7% | -8.5% |
| Income Tax Expense | (2.53M) | 0 | 33K | 330K | 0 |
| Net Income | (129.86M) | (93.09M) | (61.23M) | (40.18M) | (6.12M) |
| Net Margin | -2076.4% | — | -854.8% | -140.9% | -8.5% |
| EPS (Basic) | (36.00) | (22.82) | (13.38) | (6.69) | (0.55) |
| EPS (Diluted) | (36.00) | (22.82) | (13.38) | (6.69) | (0.55) |
| Weighted Avg Shares | 3.61M | 4.03M | 4.58M | 6M | 11.21M |
| Weighted Avg Shares (Diluted) | 3.61M | 4.03M | 4.58M | 6M | 11.21M |
Assembly Biosciences, Inc.
NASDAQ:ASMB
Intrinsic Alpha fair value
Locked
Current Price
$22.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.